Sagimet Biosciences Inc.

FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Monday, November 9, 2026, in Boston, MA with a fireside chat at 10:30am ET (link here).

The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner Ascletis Pivotal trial designed to enroll approximately 800 U.S. patients, including 450 adolescents aged 12 and older If approved, denifanstat has the potential to address a significant unmet need among approximately 10 million Americans with moderate to severe acne FOSTER CITY, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, today announced that the first patient has been dosed in AURORA, its pivotal U.S. Phase 3 clinical trial of denifanstat in adults and adolescents aged 12 years and older with moderate to severe acne.

Sagimet Biosciences pivots denifanstat to acne, with robust Phase 3 data and a fully funded U.S. registrational trial underway. SGMT trades below cash value, presenting an asymmetric risk/reward profile as the main risk is U.S. data replication, not drug discovery. Denifanstat's efficacy and tolerability profile positions it as a differentiated oral acne therapy, targeting sebum production with potential for chronic use.